Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T80/A5/H12.5 mg FDC tablet
Drug: Amlodipine 5mg capsule
Drug: T80/H12.5 mg FDC tablet

First Posted Date: 2014-05-02

Last Posted Date: 2017-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02129192

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Tokyo, Hachioji, Japan

Multiple Rising Oral Doses of BI 1060469 in Healthy Subjects and Mild Asthma Patients

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: BI 1060469 Healthy
Drug: Placebo to BI 1060469
Drug: BI 1060469 asthmatics
Drug: Placebo to BI 1060469 asthmatics

First Posted Date: 2014-04-30

Last Posted Date: 2015-08-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 131

Registration Number: NCT02126865

Locations: 🇩🇪
1333.2.1 Boehringer Ingelheim Investigational Site, Berlin, Germany

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 1026706 in Male and Female Healthy Subjects and Patients With Osteoarthritis of the Knee

Phase 1

Completed

Conditions: Osteoarthritis

Interventions: Drug: Placebo to BI 1026706
Drug: BI 1026706

First Posted Date: 2014-04-30

Last Posted Date: 2019-03-25

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 58

Registration Number: NCT02126826

Locations: 🇩🇪
1320.2.2 Boehringer Ingelheim Investigational Site, Berlin, Germany

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: Everolimus
Drug: Exemestane
Drug: BI 836845

First Posted Date: 2014-04-28

Last Posted Date: 2022-02-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 164

Registration Number: NCT02123823

Locations: 🇰🇷
National Cancer Center, Goyang, Korea, Republic of
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇦🇹
LKH-Univ. Hospital Graz, Graz, Austria

and more 35 locations

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: empagliflozin high dose
Drug: empagliflozin medium dose
Drug: empagliflozin low dose

First Posted Date: 2014-04-23

Last Posted Date: 2016-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 27

Registration Number: NCT02121483

Locations: 🇿🇦
1245.87.27003 Boehringer Ingelheim Investigational Site, Bellville, South Africa
🇿🇦
1245.87.27002 Boehringer Ingelheim Investigational Site, Pretoria, South Africa
🇲🇽
1245.87.52001 Boehringer Ingelheim Investigational Site, Chihuahua, Mexico

and more 8 locations

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Linagliptin
Drug: Linagliptin/Metformin ER FDC
Drug: Metformin ER

First Posted Date: 2014-04-23

Last Posted Date: 2016-08-04

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 74

Registration Number: NCT02121509

Locations: 🇩🇪
1288.10.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany

A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration

Phase 2

Completed

Conditions: Wet Macular Degeneration

Interventions: Drug: BI 144807

First Posted Date: 2014-04-23

Last Posted Date: 2016-06-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 14

Registration Number: NCT02121522

Locations: 🇩🇪
1313.20.49003 Boehringer Ingelheim Investigational Site, Tübingen, Germany
🇩🇪
1313.20.49002 Boehringer Ingelheim Investigational Site, Leipzig, Germany
🇩🇪
1313.20.49004 Boehringer Ingelheim Investigational Site, Bonn, Germany

and more 7 locations

Bioequivalence Study of Telmisartan Between T80/A5/H12.5 mg FDC Tablet and T80/A5 mg Tab and H12.5 mg Tab Concomitant Use

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: T80/A5 mg FDC tablet
Drug: T80/A5/H12.5 ng FDC tablet
Drug: H12.5 mg tablet
Drug: T80/A5/H12.5 mg FDC tablet
Drug: H12.5 mf tablet

First Posted Date: 2014-04-23

Last Posted Date: 2017-04-12

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT02121535

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Kanagawa, Yokohama, Japan

A Study to Investigate the Phototoxic Potential of Faldaprevir

Phase 1

Withdrawn

Conditions: Healthy

Interventions: Drug: Faldaprevir high dose
Drug: Faldaprevir low dose
Drug: Placebo
Drug: Ciprofloxacin

First Posted Date: 2014-04-15

Last Posted Date: 2014-06-25

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT02114671

Locations: 🇬🇧
1241.42.44001 Boehringer Ingelheim Investigational Site, Edinburgh, United Kingdom

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 187004
Drug: metformin

First Posted Date: 2014-04-10

Last Posted Date: 2016-01-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 16

Registration Number: NCT02109679

Locations: 🇩🇪
1307.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy